Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4157268 | 0.79 | PNMT (0.58) | PNMTOPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4139253 | 0.77 | PNMT (0.55) | PNMTOPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4601149 | 0.77 | PNMT (0.55) | PNMTOPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL27946000 | 0.76 | PNMT (0.53) | PNMTOPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL4387326 | 0.76 | IDO1 (0.57) | PNMTOPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL8463699 | 0.74 | PNMT (0.51) | PNMTOPRK1EPHX1IDO1TDO2 | |
| SCHEMBL4069772 | 0.74 | PNMT (0.51) | PNMTOPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL12971482 | 0.74 | PNMT (0.51) | PNMTOPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL22193351 | 0.74 | PNMT (0.61) | PNMTIDO1TDO2CES2ACP3 | |
| SCHEMBL7647822 | 0.74 | PNMT (0.51) | PNMTOPRL1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663476-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2947067-A1 | Glycine transporter-1 inhibitors | Amgen, Inc (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150307457-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-8735383-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2041088-B1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC (US) | 2014-01-08 | — | — | EP | disclosed |
| EP-2565183-A1 | Glycine transporter-1 inhibitors | Amgen Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| CN-101479243-B | Glycine transporter-1 inhibitors | AMGEN INC | 2013-01-02 | — | — | CN | disclosed |
| US-20120195985-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2012-08-02 | — | — | US | disclosed |
| US-8183244-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090227595-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | HITCHCOCK STEPHEN | 2009-09-10 | — | — | US | disclosed |
| CN-101479243-A | Glycine transporter-1 inhibitors | AMGEN INC (US) | 2009-07-08 | — | — | CN | disclosed |
| US-7538114-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-2041088-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | Amgen Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008002583-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | AMGEN INC. | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227595-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC7A11, SLC6A5 | PNMT 131/4885OPRL1 723/4885OPRM1 1216/4885 |
| US-20120195985-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC6A5, SLC1A2 | PNMT 159/4885OPRL1 594/4885OPRM1 1113/4885 |
| US-20080004289-A1 | Glycine transporter-1 inhibitors | SLC18A2, SLC7A11, SLC6A5 | PNMT 131/4885OPRL1 723/4885OPRM1 1216/4885 |
| US-20150307457-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC7A11, SLC6A5 | PNMT 131/4885OPRL1 723/4885OPRM1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.